The research, which garnered “Abstract of the Year” honors at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, demonstrates the potential of the targeted agent to significantly improve survival rates in AML.
More than 20,000 people will be diagnosed with acute myeloid leukemia (AML) in 2023, according to estimates from the American Cancer Society. However, new findings from a multicenter, phase 3 trial suggest that a high-dose, molecularly targeted radiation treatment may allow life-saving bone marrow transplants, contributing to durable complete remission (dCR) at six months in greater than 60 percent of patients with relapsed or refractory AML.
For the study, which received “Abstract of the Year” honors at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Chicago, researchers examined the use of Iomab-B (131-I apamistamab) and subsequent allogeneic hematopoietic cell transplant (HCT) in patients with relapsed or refractory AML. According to the study authors, Iomab-B facilitates myeloablation and eradication of leukemic cells via high-dose, molecular-targeted radiation of hematopoietic cells.
The researchers found that all 66 patients who received Iomab-B underwent HCT in comparison to 14 patients (18.2 percent) who received conventional care in the form of high-dose chemotherapy. Twenty-two percent of the Iomab-B cohort achieved dCR at six months and none of the patients in the conventional care group achieved this primary endpoint. Forty-four patients in the conventional care arm of the study crossed over to the Iomab-B treatment group and 40 of the patients subsequently had HCT, according to the study.
For additional content from SNMMI 2023, click here.
In comparison to patients who did not crossover to the Iomab-B arm of the study, those who were treated with Iomab-B had double the survival rate at one year, according to the study authors. The researchers also noted long-term survival of two years or greater in 60 percent of patients who had dCR after treatment with Iomab-B.
“This pivotal study showed that a single personalized dose of Iomab-B enabled all patients who received the therapeutic dose to have access to potentially curative bone marrow transplant compared to only 17 percent of patients who received conventional care. Iomab-B also demonstrated long-term survival benefit for patients who met the primary endpoint, and safety of the Iomab-B led regimen was excellent,” noted lead study author Neeta Pandit-Taskar, M.D., the clinical director of radioimmunotherapy and theranostics at the Ludwig Center for Cancer Immunotherapy at the Memorial Sloan Kettering Cancer Center in New York, New York.
In regard to the safety profile, Pandit-Taskar and colleagues also noted over a 22 percent lower rate of sepsis for patients treated with Iomab-B and HCT (6.1 percent) in comparison to the conventional care cohort (28.6 percent). They also found that Iomab-B had lower rates of febrile neutropenia (43.9 percent versus 50 percent) and mucositis (15.2 percent versus 21.4 percent) in contrast to conventional care.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
Interventional Radiology Study Shows Low Breast Cancer Recurrence 16 Months After Cryoablation
March 29th 2024In a cohort of patients with invasive breast cancer and tumor sizes ranging between 0.3 to 9 cm, image-guided cryoablation was associated with a 10 percent recurrence rate at 16 months, according to research recently presented at the Society of Interventional Radiology (SIR) conference.
Emerging Insights on MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer
March 21st 2024For men with prostate cancer, the use of MRI-guided transurethral ultrasound ablation (TULSA) led to a 92 percent decrease in median prostate volume at one year, according to new research recently presented at Society of Interventional Radiology (SIR) conference.
Could Cloud-Based 'Progressive Loading' be a Boon for Radiology Workflows?
March 13th 2024The newly launched Progressive Loading feature, available through RamSoft’s OmegaAI software, reportedly offers radiologist rapid uploading of images that is faster than on-site networks and other cloud-based systems regardless of the network radiologists are using.
ECR Study Finds Mixed Results with AI on Breast Ultrasound
March 6th 2024While adjunctive use of AI led to significantly higher specificity and accuracy rates in detecting cancer on breast ultrasound exams in comparison to unassisted reading by breast radiologists, researchers noted that 12 of 13 BI-RADS 3 lesions upgraded by AI were ultimately benign, according to research presented at the European Congress of Radiology.